 Connection
Ihab Kamel to Neoadjuvant Therapy
This is a "connection" page, showing publications Ihab Kamel has written about Neoadjuvant Therapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.962 |
|
|
|
-
Madani SP, Mohseni A, Mirza-Aghazadeh-Attari M, Shahbazian H, Afyouni S, Borhani A, Zandieh G, Laheru D, Kamel IR. Role of volumetric tumor enhancement on CT in predicting overall survival in patients with unresectable pancreatic ductal adenocarcinoma. Clin Imaging. 2025 Jan; 117:110365.
Score: 0.188
-
Madani SP, Mirza-Aghazadeh-Attari M, Mohseni A, Afyouni S, Zandieh G, Shahbazian H, Borhani A, Yazdani Nia I, Laheru D, Pawlik TM, Kamel IR. Value of radiomics features extracted from baseline computed tomography images in predicting overall survival in patients with nonsurgical pancreatic ductal adenocarcinoma: incorporation of a radiomics score to a multiparametric nomogram to predict 1-year overall survival. J Gastrointest Surg. 2025 Feb; 29(2):101882.
Score: 0.188
-
Bai B, Cui L, Chu F, Wang Z, Zhao K, Wang S, Wang S, Yan X, Wang M, Kamel IR, Yang G, Qu J. Multiple diffusion models for predicting pathologic response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy. Abdom Radiol (NY). 2024 12; 49(12):4216-4226.
Score: 0.183
-
Ho WJ, Sharma G, Zhu Q, Stein-O'Brien G, Durham J, Anders R, Popovic A, Mo G, Kamel I, Weiss M, Jaffee E, Fertig EJ, Yarchoan M. Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy. J Immunother Cancer. 2020 11; 8(2).
Score: 0.142
-
Lu Y, Ma L, Qin J, Wang Z, Guo J, Zhao Y, Zhang H, Yan X, Liu H, Li H, Kamel IR, Qu J. The value of GRASP on DCE-MRI for assessing response to neoadjuvant chemotherapy in patients with esophageal cancer. BMC Cancer. 2019 Oct 24; 19(1):999.
Score: 0.132
-
Qu J, Zhang Y, Lu S, Xing W, Zheng Y, Sun H, Gao Q, Xia Q, Wang Z, Zhang H, Wang S, Qin J, Kamel IR, Li H. Quantitative RECIST derived from multiparametric MRI in evaluating response of esophageal squamous cell carcinoma to neoadjuvant therapy. Eur Radiol. 2022 10; 32(10):7295-7306.
Score: 0.040
-
Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, Charmsaz S, Lin D, Quong D, Wilt B, Kamel IR, Weiss M, Philosophe B, Burkhart R, Burns WR, Shubert C, Ejaz A, He J, Deshpande A, Danilova L, Stein-O'Brien G, Sugar EA, Laheru DA, Anders RA, Fertig EJ, Jaffee EM, Yarchoan M. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. Nat Cancer. 2021 09; 2(9):891-903.
Score: 0.037
-
Wang Z, Guo J, Qin J, Zhang H, Zhao Y, Lu Y, Yan X, Zhang F, Zhang Z, Zhang T, Zhang S, Dong Y, Jiang L, Grimm R, Li H, Kamel IR, Qu J. Accuracy of 3-T MRI for Preoperative T Staging of Esophageal Cancer After Neoadjuvant Chemotherapy, With Histopathologic Correlation. AJR Am J Roentgenol. 2019 04; 212(4):788-795.
Score: 0.031
-
Peng PD, Hyder O, Bloomston M, Marques H, Corona-Villalobos C, Dixon E, Pulitano C, Hirose K, Schulick RD, Barroso E, Aldrighetti L, Choti M, Shen F, Kamel I, Geschwind JF, Pawlik TM. Sequential intra-arterial therapy and portal vein embolization is feasible and safe in patients with advanced hepatic malignancies. HPB (Oxford). 2012 Aug; 14(8):523-31.
Score: 0.020
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|